Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 408 participants.
Also called NCT06350890
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 408 participants
- Registry
-
NCT06350890
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06350890. Randomized; double masking; primary purpose treatment. Start 2023-11-05 (actual); primary completion 2024-12-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
- Acronym
- SYMPHONY-1
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- HTD1801
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.
Record details
- Record id
cardio:ct-nct06350890- Content hash
d18cab552c8c6ee8cf8e8a3f5981b512f59a27cd4df38b32a71a27396dfd840c